<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758862</url>
  </required_header>
  <id_info>
    <org_study_id>TD1414-C22</org_study_id>
    <nct_id>NCT00758862</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo</brief_title>
  <official_title>The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A national, prospective single arm phase II study investigating the pharmacokinetics and
      safety of the 2% TD1414 cream when applied 3 times daily for 7 days to adult patients with
      impetigo or Secondarily Infected Traumatic Lesions (SITL). A total of 20 patients will be
      enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TD1414 Serum Concentration by Timepoint</measure>
    <time_frame>From 0 hours to 240 hours</time_frame>
    <description>On Days 1 and 2(and possibly Day 3 depending on the time of first application on Day 1) a sample was taken for pharmacokinetic(PK) analysis at any time before first application on Day 1, and at 12±1, 18±1, 24±1 and 36±4 hours after first application. If the 36±4 hours sampling time fell on Day 3, then a second sample was also required on Day 3, but was to be obtained at 6pm or afterwards. On Days 3 to 6(and also Day 7 if the very last application fell on Day 8), one sample was taken on each day at any time during the day. On Days 7 and 8(or Days 8 and 9 if very last application was on Day 8), a sample was taken immediately before the very last application and at 6±1, 12±1 and 24±2 hours after the very last application. On Days 9 and 10, one sample was taken on each day at any time during the day. If the participant had already had a sample(s) taken on Day 9 because the timing of some of the post-last application samples fell on this day, then further samples were not required on Day 9</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak TD1414 Serum Concentration (Cmax )</measure>
    <time_frame>From 0 hours to 240 hours</time_frame>
    <description>The Cmax was summarised by lesion size at baseline, by SIRS scores at baseline and by amount of TD1414 cream used.
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses. For description of lesion size, SIRS score and amount of TD1414 cream used please see outcome measure 3, 4 and 5 respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Serum Concentration by Baseline Lesion Size</measure>
    <time_frame>From 0 hours to 240 hours</time_frame>
    <description>On Day 1 (before the first application), the (sub)investigator recorded the size of the lesion(s). For each participant the size of the lesion was allocated to one of two categories: ≤15cm² or &gt;15cm². The Cmax is presented by baseline lesion size category (≤15 cm² and &gt;15 cm²).
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Serum Concentration by SIRS Score</measure>
    <time_frame>From 0 hours to 240 hours</time_frame>
    <description>On Day 1 (before the first application), the (sub)investigator recorded the severity of the lesion(s).
The severity was to be recorded using the Severity of Infection Rating Scale (SIRS).
For the SIRS, the following seven clinical signs/symptoms of infection were assessed:
Exudates/pus Crusting Erythema Oedema Tissue warmth Itching Pain
Each of the seven signs/symptoms was scored using the following scale:
0 = absent 2 = mild 4 = moderate 6 = severe The scores for each sign/symptom were summed to give the total SIRS score. The total SIRS score could range from 0 to 42.
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Serum Concentration by Amount of TD1414 Cream Used</measure>
    <time_frame>From 0 hours to 240 hours</time_frame>
    <description>The weight of TD1414 cream used was calculated by subtracting the weight of the used dispensed tube from the mean weight of a full tube.
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Peak Serum Concentration (Tmax )</measure>
    <time_frame>From 0 hours to 240 hours</time_frame>
    <description>Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Peak Serum Concentration (Tmax ) by Baseline Lesion Size</measure>
    <time_frame>From 0 hours to 240 hours</time_frame>
    <description>Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Peak Serum Concentration (Tmax ) by SIRS Score</measure>
    <time_frame>From 0 hours to 240 hours</time_frame>
    <description>Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Peak Serum Concentration (Tmax ) by Amount of TD1414 Cream Used</measure>
    <time_frame>From 0 hours to 240 hours</time_frame>
    <description>Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC(0-t))</measure>
    <time_frame>From 0 hours to 240 hours</time_frame>
    <description>Area under the concentration-time curve (AUC(0-t)) from time 0 to time of last non-zero observation after dosing, calculated by linear/log trapezoidal method.
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve by Baseline Lesion Size</measure>
    <time_frame>From 0 hours to 240 hours</time_frame>
    <description>On Day 1 (before the first application), the (sub)investigator recorded the size of the lesion(s). For each participant the size of the lesion was allocated to one of two categories: ≤15cm² or &gt;15cm².
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve by SIRS Score</measure>
    <time_frame>From 0 hours to 240 hours</time_frame>
    <description>On Day 1 (before the first application), the (sub)investigator recorded the severity of the lesion(s).
The severity was to be recorded using the Severity of Infection Rating Scale (SIRS).
For the SIRS, the following seven clinical signs/symptoms of infection were assessed:
Exudates/pus, Crusting, Erythema, Oedema, Tissue warmth, Itching and Pain.
Each of the seven signs/symptoms was scored using the following scale:
0 = absent 2 = mild 4 = moderate 6 = severe
The scores for each sign/symptom were summed to give the total SIRS score. The total SIRS score could range from 0 to 42.
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC(0-t)) by Amount of TD1414 Cream Used</measure>
    <time_frame>From 0 hours to 240 hours</time_frame>
    <description>The weight of TD1414 cream used was calculated by subtracting the weight of the used dispensed tube from the mean weight of a full tube.
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Secondarily Infected Traumatic Lesions (SITL)</condition>
  <condition>Impetigo</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2% TD1414 Cream</intervention_name>
    <description>Application 3 times daily for 7 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability and willingness to comply with all the study requirements/procedures

          -  Age ≥ 18 and ≤65 years

          -  Primary bullous/non-bullous impetigo or SITL

          -  Patients suffering from primary bullous/non-bullous impetigo must have:

               -  Not more than 10 discrete lesions, and

               -  A total lesional area ≥ 1 cm2 and ≤ 100 cm2, and

               -  Any surrounding erythema must not extend beyond 2 cm from the edge of the lesion,
                  and

               -  Total SIRS score equal to or ≥ 8

          -  Patients suffering from SITL must have:

               -  A total infected area of the traumatic lesion ≥ 1 cm2 and ≤ 100 cm2, and

               -  Any surrounding erythema must not extend beyond 2 cm from the edge of the lesion,
                  and

               -  Total SIRS score ≥ 8, and

               -  SITL not caused by burns or animal/human bite

          -  Amenable for treatment with topical antibiotic alone

          -  Body Mass Index ≥18 and ≤ 35 kg/m2.

        Exclusion Criteria:

          -  Immunosuppressed state or other serious systemic disease

          -  Signs and/or symptoms of systemic infection, such as malaise and fever or local
             adenopathy and fever

          -  Unwillingness to abstain from use of any other topical products including emollients
             on the lesional area during the study

          -  Systemic treatment with antibacterials or immunosuppressive agents (e.g.
             corticosteroids) within 2 days before day 1 (inhaled/intranasal steroids may be used)

          -  Topical treatment with antibacterials, immunosuppressive agents (e.g. corticosteroids)
             or antiseptics (e.g. alcohol, chlorhexidine, hydrogen peroxide, iodine) on the
             lesional area within 2 days before day 1

          -  Indication for surgical or systemic treatment of the SITL/impetigo

          -  Known or suspected hypersensitivity to any of the components of the study medication

          -  Participation in any other interventional clinical trial or use of an investigational
             drug within 30 days or 5 half-lives (whichever is longer) prior to day 1

          -  Previously enrolled in this study

          -  A blood alcohol content ≥ 0.08% as determined by a Breathalyzer test

          -  Known or suspected history of alcohol abuse/alcoholism or drug abuse

          -  Known or suspected impairment of liver function

          -  Heart rhythm disturbances or clinically significant quantitative or qualitative
             abnormality in the pretreatment ECG

          -  Blood donation in excess of 500mL within 56 days before day 1 or donation during the
             study or within 3 days of leaving the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terry Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>J&amp;S Studies Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>J&amp;S Studies, Inc.</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>September 23, 2008</study_first_submitted>
  <study_first_submitted_qc>September 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <results_first_submitted>June 26, 2018</results_first_submitted>
  <results_first_submitted_qc>June 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2018</results_first_posted>
  <last_update_submitted>June 26, 2018</last_update_submitted>
  <last_update_submitted_qc>June 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Impetigo</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TD1414</title>
          <description>2% TD1414 Cream: Application 3 times on lesions area(s) daily for 7 days. A maximum of 0.5g of cream on a 100 cm2 lesion area was to be used per application.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TD1414</title>
          <description>2% TD1414 Cream: Application 3 times daily for 7 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.1" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>TD1414 Serum Concentration by Timepoint</title>
        <description>On Days 1 and 2(and possibly Day 3 depending on the time of first application on Day 1) a sample was taken for pharmacokinetic(PK) analysis at any time before first application on Day 1, and at 12±1, 18±1, 24±1 and 36±4 hours after first application. If the 36±4 hours sampling time fell on Day 3, then a second sample was also required on Day 3, but was to be obtained at 6pm or afterwards. On Days 3 to 6(and also Day 7 if the very last application fell on Day 8), one sample was taken on each day at any time during the day. On Days 7 and 8(or Days 8 and 9 if very last application was on Day 8), a sample was taken immediately before the very last application and at 6±1, 12±1 and 24±2 hours after the very last application. On Days 9 and 10, one sample was taken on each day at any time during the day. If the participant had already had a sample(s) taken on Day 9 because the timing of some of the post-last application samples fell on this day, then further samples were not required on Day 9</description>
        <time_frame>From 0 hours to 240 hours</time_frame>
        <population>One participant withdrew at day 3 due to the participant being out of range of the inclusion criterion.</population>
        <group_list>
          <group group_id="O1">
            <title>TD1414</title>
            <description>2% TD1414 Cream: Application 3 times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>TD1414 Serum Concentration by Timepoint</title>
          <description>On Days 1 and 2(and possibly Day 3 depending on the time of first application on Day 1) a sample was taken for pharmacokinetic(PK) analysis at any time before first application on Day 1, and at 12±1, 18±1, 24±1 and 36±4 hours after first application. If the 36±4 hours sampling time fell on Day 3, then a second sample was also required on Day 3, but was to be obtained at 6pm or afterwards. On Days 3 to 6(and also Day 7 if the very last application fell on Day 8), one sample was taken on each day at any time during the day. On Days 7 and 8(or Days 8 and 9 if very last application was on Day 8), a sample was taken immediately before the very last application and at 6±1, 12±1 and 24±2 hours after the very last application. On Days 9 and 10, one sample was taken on each day at any time during the day. If the participant had already had a sample(s) taken on Day 9 because the timing of some of the post-last application samples fell on this day, then further samples were not required on Day 9</description>
          <population>One participant withdrew at day 3 due to the participant being out of range of the inclusion criterion.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 hours Post First Application</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="624.3" spread="1255.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 hours Post First Application</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="864.1" spread="1635.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours Post First Application</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1195.7" spread="2448.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hours Post First Application</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="888.4" spread="1878.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="659.1" spread="1461.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309.0" spread="578.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="344.4" spread="673.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.8" spread="199.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior last application</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.4" spread="220.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours Post Last Application</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.9" spread="231.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours Post Last Application</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.6" spread="214.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours Post Last Application</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.6" spread="135.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" spread="125.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2" spread="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak TD1414 Serum Concentration (Cmax )</title>
        <description>The Cmax was summarised by lesion size at baseline, by SIRS scores at baseline and by amount of TD1414 cream used.
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses. For description of lesion size, SIRS score and amount of TD1414 cream used please see outcome measure 3, 4 and 5 respectively.</description>
        <time_frame>From 0 hours to 240 hours</time_frame>
        <population>Cmax could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>TD1414</title>
            <description>2% TD1414 Cream: Application 3 times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Peak TD1414 Serum Concentration (Cmax )</title>
          <description>The Cmax was summarised by lesion size at baseline, by SIRS scores at baseline and by amount of TD1414 cream used.
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses. For description of lesion size, SIRS score and amount of TD1414 cream used please see outcome measure 3, 4 and 5 respectively.</description>
          <population>Cmax could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="650.4" spread="2433.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Serum Concentration by Baseline Lesion Size</title>
        <description>On Day 1 (before the first application), the (sub)investigator recorded the size of the lesion(s). For each participant the size of the lesion was allocated to one of two categories: ≤15cm² or &gt;15cm². The Cmax is presented by baseline lesion size category (≤15 cm² and &gt;15 cm²).
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
        <time_frame>From 0 hours to 240 hours</time_frame>
        <population>Cmax could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>TD1414</title>
            <description>2% TD1414 Cream: Application 3 times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Serum Concentration by Baseline Lesion Size</title>
          <description>On Day 1 (before the first application), the (sub)investigator recorded the size of the lesion(s). For each participant the size of the lesion was allocated to one of two categories: ≤15cm² or &gt;15cm². The Cmax is presented by baseline lesion size category (≤15 cm² and &gt;15 cm²).
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
          <population>Cmax could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=15 cm^2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="484.1" spread="1755.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;15 cm^2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1233.3" spread="3545.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Serum Concentration by SIRS Score</title>
        <description>On Day 1 (before the first application), the (sub)investigator recorded the severity of the lesion(s).
The severity was to be recorded using the Severity of Infection Rating Scale (SIRS).
For the SIRS, the following seven clinical signs/symptoms of infection were assessed:
Exudates/pus Crusting Erythema Oedema Tissue warmth Itching Pain
Each of the seven signs/symptoms was scored using the following scale:
0 = absent 2 = mild 4 = moderate 6 = severe The scores for each sign/symptom were summed to give the total SIRS score. The total SIRS score could range from 0 to 42.
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
        <time_frame>From 0 hours to 240 hours</time_frame>
        <population>Cmax could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>TD1414</title>
            <description>2% TD1414 Cream: Application 3 times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Serum Concentration by SIRS Score</title>
          <description>On Day 1 (before the first application), the (sub)investigator recorded the severity of the lesion(s).
The severity was to be recorded using the Severity of Infection Rating Scale (SIRS).
For the SIRS, the following seven clinical signs/symptoms of infection were assessed:
Exudates/pus Crusting Erythema Oedema Tissue warmth Itching Pain
Each of the seven signs/symptoms was scored using the following scale:
0 = absent 2 = mild 4 = moderate 6 = severe The scores for each sign/symptom were summed to give the total SIRS score. The total SIRS score could range from 0 to 42.
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
          <population>Cmax could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SIRS score &lt;=13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416.2" spread="1937.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SIRS score &gt;13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1068.3" spread="2931.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Serum Concentration by Amount of TD1414 Cream Used</title>
        <description>The weight of TD1414 cream used was calculated by subtracting the weight of the used dispensed tube from the mean weight of a full tube.
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
        <time_frame>From 0 hours to 240 hours</time_frame>
        <population>Cmax could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>TD1414</title>
            <description>2% TD1414 Cream: Application 3 times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Serum Concentration by Amount of TD1414 Cream Used</title>
          <description>The weight of TD1414 cream used was calculated by subtracting the weight of the used dispensed tube from the mean weight of a full tube.
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
          <population>Cmax could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=2 g</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="323.5" spread="858.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;2 g</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1081.0" spread="2976.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Peak Serum Concentration (Tmax )</title>
        <description>Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
        <time_frame>From 0 hours to 240 hours</time_frame>
        <population>Tmax could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>TD1414</title>
            <description>2% TD1414 Cream: Application 3 times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Peak Serum Concentration (Tmax )</title>
          <description>Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
          <population>Tmax could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.08" spread="59.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Peak Serum Concentration (Tmax ) by Baseline Lesion Size</title>
        <description>Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
        <time_frame>From 0 hours to 240 hours</time_frame>
        <population>Tmax could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>TD1414</title>
            <description>2% TD1414 Cream: Application 3 times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Peak Serum Concentration (Tmax ) by Baseline Lesion Size</title>
          <description>Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
          <population>Tmax could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=15 cm^2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.42" spread="56.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;15 cm^2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.73" spread="69.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Peak Serum Concentration (Tmax ) by SIRS Score</title>
        <description>Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
        <time_frame>From 0 hours to 240 hours</time_frame>
        <population>AUC(0-t) could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>TD1414</title>
            <description>2% TD1414 Cream: Application 3 times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Peak Serum Concentration (Tmax ) by SIRS Score</title>
          <description>Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
          <population>AUC(0-t) could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=13 cm^2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.21" spread="62.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;13 cm^2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.22" spread="58.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Peak Serum Concentration (Tmax ) by Amount of TD1414 Cream Used</title>
        <description>Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
        <time_frame>From 0 hours to 240 hours</time_frame>
        <population>Tmax could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>TD1414</title>
            <description>2% TD1414 Cream: Application 3 times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Peak Serum Concentration (Tmax ) by Amount of TD1414 Cream Used</title>
          <description>Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
          <population>Tmax could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=2 g</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.15" spread="63.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;2 g</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.65" spread="62.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC(0-t))</title>
        <description>Area under the concentration-time curve (AUC(0-t)) from time 0 to time of last non-zero observation after dosing, calculated by linear/log trapezoidal method.
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
        <time_frame>From 0 hours to 240 hours</time_frame>
        <population>AUC(0-t) could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>TD1414</title>
            <description>2% TD1414 Cream: Application 3 times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC(0-t))</title>
          <description>Area under the concentration-time curve (AUC(0-t)) from time 0 to time of last non-zero observation after dosing, calculated by linear/log trapezoidal method.
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
          <population>AUC(0-t) could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32138" spread="123032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve by Baseline Lesion Size</title>
        <description>On Day 1 (before the first application), the (sub)investigator recorded the size of the lesion(s). For each participant the size of the lesion was allocated to one of two categories: ≤15cm² or &gt;15cm².
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
        <time_frame>From 0 hours to 240 hours</time_frame>
        <population>AUC(0-t) could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>TD1414</title>
            <description>2% TD1414 Cream: Application 3 times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve by Baseline Lesion Size</title>
          <description>On Day 1 (before the first application), the (sub)investigator recorded the size of the lesion(s). For each participant the size of the lesion was allocated to one of two categories: ≤15cm² or &gt;15cm².
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
          <population>AUC(0-t) could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=15 cm^2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21240" spread="61954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;15 cm^2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78836" spread="192236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve by SIRS Score</title>
        <description>On Day 1 (before the first application), the (sub)investigator recorded the severity of the lesion(s).
The severity was to be recorded using the Severity of Infection Rating Scale (SIRS).
For the SIRS, the following seven clinical signs/symptoms of infection were assessed:
Exudates/pus, Crusting, Erythema, Oedema, Tissue warmth, Itching and Pain.
Each of the seven signs/symptoms was scored using the following scale:
0 = absent 2 = mild 4 = moderate 6 = severe
The scores for each sign/symptom were summed to give the total SIRS score. The total SIRS score could range from 0 to 42.
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
        <time_frame>From 0 hours to 240 hours</time_frame>
        <population>AUC(0-t) could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>TD1414</title>
            <description>2% TD1414 Cream: Application 3 times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve by SIRS Score</title>
          <description>On Day 1 (before the first application), the (sub)investigator recorded the severity of the lesion(s).
The severity was to be recorded using the Severity of Infection Rating Scale (SIRS).
For the SIRS, the following seven clinical signs/symptoms of infection were assessed:
Exudates/pus, Crusting, Erythema, Oedema, Tissue warmth, Itching and Pain.
Each of the seven signs/symptoms was scored using the following scale:
0 = absent 2 = mild 4 = moderate 6 = severe
The scores for each sign/symptom were summed to give the total SIRS score. The total SIRS score could range from 0 to 42.
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
          <population>AUC(0-t) could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SIRS score &lt;=13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17923" spread="69972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SIRS score &gt;13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61488" spread="160681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC(0-t)) by Amount of TD1414 Cream Used</title>
        <description>The weight of TD1414 cream used was calculated by subtracting the weight of the used dispensed tube from the mean weight of a full tube.
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
        <time_frame>From 0 hours to 240 hours</time_frame>
        <population>AUC(0-t) could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>TD1414</title>
            <description>2% TD1414 Cream: Application 3 times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC(0-t)) by Amount of TD1414 Cream Used</title>
          <description>The weight of TD1414 cream used was calculated by subtracting the weight of the used dispensed tube from the mean weight of a full tube.
Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.</description>
          <population>AUC(0-t) could not be calculated for one participant as all values below lower limit of quantification (TD1414 concentration = 50pg/mL).</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=2 g</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13642" spread="23828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;2 g</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59932" spread="150278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Day 1 to Day 10</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TD1414</title>
          <description>2% TD1414 Cream: Application 3 times daily for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Company acknowledges the investigator’s right to publish the entire results of the study, irrespective of outcome. The Company retains the right to have any publication submitted to the Company for review at least 30 days prior to the same paper being submitted for publication or presentation. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Manager</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <phone>+45 4494 5888</phone>
      <email>disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

